Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kuros Biosciences AG (KURN.SW)
Schlieren, CH
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.09% | -2.56% | +5.23% | -21.14% | -33.31% | -20.01% | -18.74% | +1,504.51% | +967.00% | -26.24% | -99.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+60.5% ★ Q4'25: +219.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+151.3% ★ Q4'25: +138.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-6.1% Q4'25: +1.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+6.0% ★ Q4'25: +6.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+8.0% ★ Q4'25: +28.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+11.3% Q4'25: +9.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.39× ★ Q4'25: 0.17× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.36M
est: 5.00M (+27.1%)
|
534.0K
est: 966.4K (-44.7%)
|
715.0K
est: 98.7K (+624.7%)
|
2.56M
est: 2.61M (-1.9%)
|
4.04M
est: 3.70M (+9.0%)
|
13.82M
est: 13.37M (+3.3%)
|
17.99M
est: 19.44M (-7.5%)
|
33.56M
est: 30.64M (+9.5%)
|
75.56M
est: 78.69M (-4.0%)
|
121.30M
est: 117.88M (+2.9%)
|
157.35M
141.26M – 173.45M
+33.5% YoY
|
200.42M
179.92M – 220.92M
+27.4% YoY
|
247.24M
221.94M – 272.53M
+23.4% YoY
|
298.20M
267.70M – 328.71M
+20.6% YoY
|
349.25M
313.52M – 384.98M
+17.1% YoY
|
| EBITDA |
-4.06M
est: -2.09M (-94.9%)
|
-15.10M
est: -403.1K (-3,644.9%)
|
-11.74M
est: -41.2K (-28,424.9%)
|
-8.46M
est: -1.09M (-676.8%)
|
-8.58M
est: -1.55M (-455.1%)
|
-5.29M
est: -5.58M (+5.2%)
|
-8.84M
est: -8.11M (-9.0%)
|
-6.84M
est: -12.78M (+46.5%)
|
-561.0K
est: -15.77M (+96.4%)
|
10.13M
est: -23.63M (+142.9%)
|
-31.54M
-34.76M – -28.31M
-33.5% YoY
|
-40.17M
-44.28M – -36.06M
-27.4% YoY
|
-49.55M
-54.62M – -44.48M
-23.4% YoY
|
-59.77M
-65.88M – -53.65M
-20.6% YoY
|
-70.00M
-77.16M – -62.84M
-17.1% YoY
|
| EBIT |
-4.07M
est: -2.57M (-58.4%)
|
-16.20M
est: -496.4K (-3,163.2%)
|
-13.69M
est: -50.7K (-26,903.5%)
|
-11.17M
est: -1.34M (-733.2%)
|
-11.25M
est: -1.90M (-491.0%)
|
-8.17M
est: -6.87M (-18.9%)
|
-11.67M
est: -9.98M (-16.9%)
|
-9.59M
est: -15.74M (+39.1%)
|
-3.20M
est: -23.74M (+86.5%)
|
7.33M
est: -35.56M (+120.6%)
|
-47.46M
-52.32M – -42.61M
-33.5% YoY
|
-60.45M
-66.64M – -54.27M
-27.4% YoY
|
-74.57M
-82.20M – -66.94M
-23.4% YoY
|
-89.95M
-99.15M – -80.75M
-20.6% YoY
|
-105.34M
-116.12M – -94.57M
-17.1% YoY
|
| Net Income |
6.23M
est: -1.93B (+100.3%)
|
-16.48M
est: -41.56M (+60.3%)
|
-11.69M
est: -31.26M (+62.6%)
|
-11.25M
est: -24.43M (+53.9%)
|
-11.52M
est: -20.31M (+43.3%)
|
-7.54M
est: -7.93M (+4.9%)
|
-14.60M
est: -13.93M (-4.8%)
|
-13.73M
est: -10.42M (-31.7%)
|
-3.72M
est: -408.7K (-809.2%)
|
2.12M
est: 5.59M (-62.1%)
|
10.09M
8.75M – 11.43M
+80.4% YoY
|
21.10M
17.65M – 24.54M
+109.1% YoY
|
38.74M
33.59M – 43.89M
+83.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
7.37M
est: 3.79M (+94.5%)
|
1.82M
est: 732.3K (+148.8%)
|
8.93M
est: 74.8K (+11,848.5%)
|
7.27M
est: 1.98M (+267.7%)
|
4.70M
est: 2.81M (+67.2%)
|
7.38M
est: 10.13M (-27.2%)
|
11.15M
est: 14.73M (-24.3%)
|
31.09M
est: 23.22M (+33.9%)
|
41.26M
est: 52.84M (-21.9%)
|
88.60M
est: 79.15M (+11.9%)
|
105.65M
94.84M – 116.46M
+33.5% YoY
|
134.57M
120.80M – 148.33M
+27.4% YoY
|
166.00M
149.02M – 182.98M
+23.4% YoY
|
200.22M
179.74M – 220.70M
+20.6% YoY
|
234.49M
210.51M – 258.48M
+17.1% YoY
|
| EPS |
1.60
est: -51.90 (+103.1%)
|
-1.88
est: -1.12 (-68.3%)
|
-1.14
est: -0.84 (-35.6%)
|
-0.66
est: -0.66 (-0.5%)
|
-0.47
est: -0.55 (+13.9%)
|
-0.23
est: -0.21 (-7.9%)
|
-0.43
est: -0.37 (-14.8%)
|
-0.38
est: -0.28 (-35.6%)
|
-0.10
est: -0.01 (-911.6%)
|
0.06
est: 0.14 (-59.2%)
|
0.24
0.21 – 0.28
+80.4% YoY
|
0.51
0.43 – 0.59
+109.1% YoY
|
0.94
0.81 – 1.06
+83.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Ageing Population UCITS ETF AGED.L | 0.07% | 607.8K | 0.40% |
| 2 | iShares International Small-Cap Equity Factor ETF ISCF | 0.06% | 412.5K | 0.24% |
| 3 | iShares MSCI Europe Small-Cap ETF IEUS | 0.05% | 82.9K | 0.41% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.05% | 1.60M | 0.30% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 387.4K | 0.40% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.04% | 121.0K | 0.23% |
| 7 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.04% | 121.0K | 0.23% |
| 8 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.03% | 2.35M | 0.10% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 45.1K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.72M | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher T. Fair | Chief Executive Officer & Director | 708.8K | male |
| Joost D. de Bruijn | President of Innovation and Strategy & Executive Director | 572.6K | — |
| Daniel Geiger | Chief Financial Officer | 431.2K | male |
| John Griffin | Chief Business Officer | — | male |
| G. Joseph Ross | Senior Vice President of Marketing & Business Development | — | male |
| Philippe Saudan | Senior Vice President of Quality, Regulatory & Clinical | — | — |
| Sjoerd Musters | Chief Operating Officer | — | male |
| Virginia Jamieson | Consultant | — | — |
| Laura Rosa | Senior Vice President of Global Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KURN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
